State Of Wisconsin Investment Board Tricida, Inc. Transaction History

State Of Wisconsin Investment Board

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$8.51 - $13.6 $216,749 - $346,392	25,470 New	25,470 $267,000
Q2 2021 Aug 12, 2021	SELL	$3.95 - $5.41 $159,185 - $218,023	-40,300 Closed	0 $0
Q4 2020 Feb 03, 2021	SELL	$4.37 - $9.46 $21,850 - $47,300	-5,000 Reduced 11.04%	40,300 $284,000
Q3 2020 Nov 16, 2020	SELL	$8.56 - $26.93 $856 - $2,693	-100 Reduced 0.22%	45,300 $410,000
Q2 2020 Aug 12, 2020	BUY	$21.21 - $31.55 $150,591 - $224,005	7,100 Added 18.54%	45,400 $1.25 Million
Q1 2020 May 06, 2020	BUY	$18.43 - $38.04 $103,208 - $213,024	5,600 Added 17.13%	38,300 $843,000
Q3 2019 Nov 12, 2019	BUY	$29.87 - $42.22 $203,116 - $287,096	6,800 Added 26.25%	32,700 $1.01 Million
Q2 2019 Aug 14, 2019	BUY	$31.16 - $39.46 $324,064 - $410,384	10,400 Added 67.1%	25,900 $1.02 Million
Q1 2019 May 13, 2019	BUY	$19.96 - $38.62 $71,856 - $139,032	3,600 Added 30.25%	15,500 $599,000
Q4 2018 Feb 11, 2019	SELL	$23.57 - $32.33 $2,357 - $3,233	-100 Reduced 0.83%	11,900 $281,000
Q3 2018 Nov 14, 2018	BUY	$22.5 - $39.35 $270,000 - $472,200	12,000 New	12,000 $367,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of State Of Wisconsin Investment Board, based on Form 13F filings with the SEC.

Stay updated on State Of Wisconsin Investment Board with notifications on news.